Every New Listing. Bursa and Beyond.
Your go-to hub for upcoming IPOs on Bursa Malaysia and the U.S. markets—featuring the latest listings, key insights, and everything you need before they hit the market.
The Next Big Stock Story Hasn't Been Told Yet.
Every company that trades billions in ringgit or dollars today started with a single listing morning. Some of the biggest names in the market were once unfamiliar tickers that few investors recognised.
With new IPOs launching on Bursa Malaysia and Wall Street every week, staying informed can make all the difference. Our IPO Hub keeps you updated on upcoming listings before they hit the market, so the next time someone says,
"Nobody saw that coming," you can say you did.
FEATURED UPCOMING IPO
An 8-Month-Old Biotech Wants a USD1.2 Billion Nasdaq Valuation
Braveheart Bio (BRVE) is a clinical-stage heart-drug developer backed by leading healthcare investors, with no approved product or commercial revenue yet.
​​​​​​​Braveheart Bio, Inc. (BRVE)
Founded in 2024, Braveheart Bio is developing BHB-1893, an oral cardiac myosin inhibitor for obstructive and non-obstructive hypertrophic cardiomyopathy. The drug was licensed from Jiangsu Hengrui Pharmaceuticals in 2025.
Why Investors Are Watching
Elite Backing
Backed by a16z Bio + Health, Forbion and OrbiMed, with Fidelity indicating non-binding interest in up to USD75 million of IPO shares.
Experienced Leadership
CEO Travis Murdoch previously founded and sold HI-Bio for USD1.8 billion, while former Biogen CEO Chris Viehbacher serves as Chairman.
Phase 3 Plans
Global Phase 3 trials are planned for 2H2026 and 1H2027, with IPO proceeds expected to fund operations through 2029.
Investment Strengths
- Phase 2 data reported meaningful reductions in heart obstruction and improvements in key cardiac biomarkers versus placebo.
- BHB-1893 may offer a simpler dosing profile than currently approved cardiac myosin inhibitors.
- Targets a large, underserved hypertrophic cardiomyopathy patient population.
- Strong institutional backing and an experienced biotech leadership team.
What Investors Should Watch
- Pre-revenue company with no approved products and a FY2025 net loss of USD66.1 million.
- Braveheart has not yet independently run a global clinical trial.
- The proposed valuation is a significant step-up from its late-2025 Series A fundraising.
- A single-asset investment facing approved competitors and several years of clinical and regulatory risk.
IPO Overview
Braveheart offers investors exposure to a potentially differentiated heart therapy, but its USD1.2 billion valuation depends heavily on BHB-1893 successfully completing global trials and reaching commercialisation.
FEATURED RECENT US IPO
Jersey Mike's Makes NYSE Debut
The Blackstone-backed sandwich chain raised approximately USD1.0 billion in one of the largest U.S. consumer IPOs of 2026, but shares slipped on their first day of trading.
​​​​​​​Jersey Mike's priced its IPO at USD23.00 per share, raising approximately USD1.0 billion. Shares closed their first trading day at USD21.62, down 6.0%, as investors weighed the company's long-term expansion plans against its valuation.
Bursa IPOs
As of 17 July 2026
SRKK AI BERHAD
- Provides digital transformation solutions.
- Strong presence in Malaysia & Singapore.
- Earnings growth expected to continue.
- Serves enterprise & government clients.
- Benefits from AI adoption trends.
Enest Group Bhd
Stratus Global Holdings Bhd
- Specializes in cleanroom AMHS solutions.
- Earnings expected to grow strongly.
- Debt-free balance sheet
- Exposure to AI-driven fab expansion.
- Software-integrated AMHS platform.
US IPOs
As of 5 Aug 2026.png)
Csquare (CSQR)
- AI-focused data centre infrastructure platform.
- Raised USD882M at IPO.
- Market cap of approximately USD4.2B at listing.
Jersey Mike's Subs (JMKE)
- One of the largest U.S. restaurant IPOs in recent years.
- Over 3,300 locations with a 99% franchised model.
- Raised approximately USD1.0B in its IPO.
Braveheart Bio (BRVE)
- Developing a potential treatment for hypertrophic cardiomyopathy.
- Backed by leading healthcare investors including a16z Bio + Health, Forbion and OrbiMed.
- IPO proceeds expected to fund Phase 3 clinical trials and operations through 2029.
New to IPOs? Here's How It Actually Works
A company announces it's going public. On listing day, its shares begin trading on the stock exchange. While the destination is the same, the journey differs between Bursa Malaysia and the U.S. markets—and understanding those differences helps you invest with greater confidence.
What This Means For You, Practically
Before Listing Day
Review the indicative price range, company facts and expected listing timeline before making a decision.
On Listing Day
Once the stock is listed, the market sets the live price. You can start trading through your Rakuten Trade account.
After Listing Day
Monitor post-listing movement, price swings and market updates before deciding your next action.
Why Trade IPOs?
The Upside is Real. So is the Risk.
- Start from day one — Everyone enters at the same starting line when a company begins trading on Bursa Malaysia or the U.S. markets.
- Access tomorrow's market leaders — Explore companies across emerging sectors and established industries as they make their public debut.
- Opportunity comes with volatility — Newly listed stocks can move sharply in either direction, making research and risk management essential.
Watch & Learn: Bursa IPOs
SRKK AI IPO
Opportunity or Hype?
SkyeChip IPO
AI Boom = Opportunity?
EI Power IPO
Malaysia's Next Power Play?
Empire Sushi IPO
Worth A Bite?
New to Investing? Start Here
Everything you need to start trading with confidence.
OPEN YOUR CASH UPFRONT ACCOUNT
Start investing across Bursa, US and HK markets.
DISCOVER RAKU-INVEST
Build your portfolio through regular investing.
TRADE U.S. STOCKS IN USD & MYR
Learn how to trade U.S. stocks using both USD and MYR.
START TRADING U.S. STOCKS
Own U.S. stocks from as little as 0.01 fractional shares.
Don't Just Watch. Trade It.
New companies go public on Bursa Malaysia and the U.S. markets every week. Stay informed with the latest upcoming IPOs and be ready to trade from day one.
